Sinusitis - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 93 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Sinusitis - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Sinusitis - Pipeline Review, H2 2016', provides an overview of the Sinusitis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Sinusitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sinusitis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Sinusitis
- The report reviews pipeline therapeutics for Sinusitis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Sinusitis therapeutics and enlists all their major and minor projects
- The report assesses Sinusitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Sinusitis

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Sinusitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding  Sinusitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Sinusitis Overview 7
Therapeutics Development 8
Pipeline Products for Sinusitis - Overview 8
Sinusitis - Therapeutics under Development by Companies 9
Sinusitis - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Sinusitis - Products under Development by Companies 14
Sinusitis - Companies Involved in Therapeutics Development 15
AmpliPhi Biosciences Corporation 15
F. Hoffmann-La Roche Ltd. 16
Knopp Biosciences LLC 17
Kyorin Pharmaceutical Co., Ltd. 18
Kyowa Hakko Kirin Co., Ltd. 19
Merck & Co., Inc. 20
Oticpharma Ltd 21
Paratek Pharmaceuticals, Inc. 22
Pfizer Inc. 23
Quorum Innovations LLC 24
Regeneron Pharmaceuticals Inc 25
Therabron Therapeutics, Inc. 26
Sinusitis - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
ABSA-01 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
benralizumab - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
CG-201 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
dexpramipexole dihydrochloride - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
dupilumab - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
fluticasone propionate - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
KRPAM-1977X - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
omadacycline tosylate - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
omalizumab - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
P-008 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
PCL-1404 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
PF-06817024 - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
Qi-117 - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
RG-6149 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
Small Molecule for Sinusitis - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Small Molecule to Inhibit Soluble Epoxide Hydrolase for Sinusitis and Allergic Rhinitis - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
Small Molecules for Chronic Rhinosinusitis - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
solithromycin - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
Sinusitis - Dormant Projects 86
Sinusitis - Product Development Milestones 87
Featured News & Press Releases 87
Aug 09, 2016: AmpliPhi Biosciences Confirms Clinical Trial Progress 87
Aug 03, 2016: AmpliPhi Biosciences Completes Enrollment of Its Investigational Phage Therapy Trial Targeting Staphylococcus aureus 87
Apr 20, 2016: AmpliPhi Biosciences Provides Update on Phase I Trial: Phage Therapy Well Tolerated in First Cohort 88
Feb 03, 2016: Nasal polyps can be treated with medicine dupilumab 88
Feb 02, 2016: Sanofi and Regeneron Announce Publication of Positive Phase 2 Dupilumab Data in the Journal of the American Medical Association 89
Jan 20, 2016: AmpliPhi Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial of AB-SA01 89
Nov 19, 2015: AmpliPhi Signs Clinical Trial Agreement with University of Adelaide to Conduct a Phase I Trial of Bacteriophage Therapy for Treating Staphylococcus aureus Infections 90
Jun 23, 2015: Jubilant Life Sciences receives ANDA approval for Levofloxacin Tablets 90
Sep 30, 2014: Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 91
Appendix 92
Methodology 92
Coverage 92
Secondary Research 92
Primary Research 92
Expert Panel Validation 92
Contact Us 92
Disclaimer 93

List of Tables

Number of Products under Development for Sinusitis, H2 2016 8
Number of Products under Development by Companies, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Development, H2 2016 13
Products under Development by Companies, H2 2016 14
Sinusitis - Pipeline by AmpliPhi Biosciences Corporation, H2 2016 15
Sinusitis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 16
Sinusitis - Pipeline by Knopp Biosciences LLC, H2 2016 17
Sinusitis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016 18
Sinusitis - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016 19
Sinusitis - Pipeline by Merck & Co., Inc., H2 2016 20
Sinusitis - Pipeline by Oticpharma Ltd, H2 2016 21
Sinusitis - Pipeline by Paratek Pharmaceuticals, Inc., H2 2016 22
Sinusitis - Pipeline by Pfizer Inc., H2 2016 23
Sinusitis - Pipeline by Quorum Innovations LLC, H2 2016 24
Sinusitis - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 25
Sinusitis - Pipeline by Therabron Therapeutics, Inc., H2 2016 26
Assessment by Monotherapy Products, H2 2016 27
Number of Products by Stage and Target, H2 2016 29
Number of Products by Stage and Mechanism of Action, H2 2016 31
Number of Products by Stage and Route of Administration, H2 2016 33
Number of Products by Stage and Molecule Type, H2 2016 35
Sinusitis - Dormant Projects, H2 2016 86